PF 610355

Drug Profile

PF 610355

Alternative Names: PF-00610355; PF-610,355

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antiasthmatics; Benzeneacetamides; Sulfonamides
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-I for Asthma in Belgium (Inhalation)
  • 11 Aug 2011 Discontinued - Phase-II for Asthma in Germany (Inhalation)
  • 11 Aug 2011 Discontinued - Phase-II for Asthma in Sweden (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top